안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
• 5분 읽기
• 2025년 10월 12일 게시
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 18일 게시
기사 읽기
Whenever politicians start rattling their sabres about drug prices, my first instinct is to roll my eyes. It’s usually just noise, a bit of theatre for the evening news before everyone goes back to business as usual. This time, however, I think something might actually be different. The recent agreements coming out of the Trump administration feel less like a passing storm and more like a fundamental shift in the climate for healthcare investing. For those of us with money in the game, it’s time to pay attention.
The core idea is almost insultingly simple. It’s called ‘most-favoured-nation’ pricing, which is a fancy way of saying Americans should stop paying wildly more for the same pills than people in Canada or Europe. For decades, the U.S. market has been the golden goose for big pharma, where high prices effectively subsidised cheaper drugs for the rest of the world. That party, it seems, could be coming to an end.
This isn't just about shaving a few quid off a prescription. It’s a potential earthquake for business models that have been built on the foundation of that American premium. If you want to get into the nitty gritty of it all, the Pharmaceutical Policy Shift Explained | Pricing Models is a fascinating, if slightly terrifying, read. The bottom line is that companies will have to adapt, and quickly, or risk being left behind.
In any shake up, there are those who sink and those who swim. To me, a company like Eli Lilly looks interesting. With a hefty manufacturing footprint already in the U.S. and a solid portfolio of drugs people genuinely need, it seems well placed to handle the pressure. Having your factories close to your biggest market suddenly becomes a rather large advantage when margins are being squeezed.
Then you have the giants like Merck. Its strength lies in diversification and its pipeline of innovative cancer treatments and vaccines. When you have a truly groundbreaking therapy, you can still command a decent price, regardless of the political winds. And let’s not forget the middlemen. A company like CVS Health, which sits at the crossroads of insurance and retail pharmacy, could actually benefit. If drugs become cheaper, more people might use them, meaning more volume and more business. It’s a different way to play the game, focusing on the plumbing of the system rather than just the drug creators.
Of course, this all comes with a healthy dose of risk. The pharmaceutical sector is a minefield of patent cliffs, clinical trial failures, and regulatory headaches at the best of times. This policy shift just adds another layer of uncertainty. The companies that will likely thrive are the ones that are nimble, efficient, and already have a strong domestic presence. Those heavily reliant on importing drugs to the U.S. at inflated prices could be in for a rough ride.
This transformation will not happen overnight. It will be a slow, grinding process, which gives savvy investors time to assess the landscape. The key, I think, is to look for resilience. Which companies have the operational muscle and the innovative spark to not just survive, but prosper in a world where the old pricing rules no longer apply? Finding them could be the prescription for a very healthy portfolio.
전체 바스켓 보기:Pharmaceutical Policy Shift Explained | Pricing Models
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 18일 게시
기사 읽기